Formation Bio, a pioneering startup in AI-driven drug development backed by OpenAI CEO Sam Altman, has raised $372 million in a Series D funding round led by Andreessen Horowitz, bringing its total funding to over $600 million. The company aims to streamline clinical trials and drug development processes, leveraging AI to enhance efficiency in areas such as study startup, participant recruitment, and data management. The funding will be primarily allocated to partnership acquisition and R&D. Formation Bio, formerly known as TrialSpark, was co-founded in 2016 by Benjamine Liu and Linhao Zhang, combining expertise in computational biology and software development. The company has three drug candidates in its pipeline, with the most advanced targeting chronic hand eczema, currently in phase 3 trials. Their recent collaboration with OpenAI and Sanofi aims to develop customized AI solutions for drug development, although it raises potential conflict-of-interest concerns due to Altman’s involvement. The AI in drug discovery market is expected to reach $4.9 billion by 2028, with several other startups also making significant strides in the field.
Formation Bio Secures $372M to Revolutionize Drug Development with AI
Formation Bio raises $372M to innovate drug development using AI technology.
1–2 minutes
TOP STORIES
Sony Music and Warner Music have sued Anthropic, accusing it of copyright infringement in AI training …
Huang believes Nvidia’s position in AI will lead to another year of record growth …
Anthropic’s report reveals a surge in distillation attacks by Chinese AI firms on U.S. models …
AI agents’ autonomy poses significant risks, as demonstrated by a recent breach …
IDScan has confirmed a data breach that exposed driver’s licenses of over 150 million individuals …
Matt Mullenweg has been placed on leave by Automattic’s board, stirring controversy …
